Triumph Capital Management Regeneron Pharmaceuticals, Inc. Transaction History
Triumph Capital Management
- $325 Million
- Q3 2025
A detailed history of Triumph Capital Management transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Triumph Capital Management holds 465 shares of REGN stock, worth $322,477. This represents 0.08% of its overall portfolio holdings.
Number of Shares
465
Previous 465
-0.0%
Holding current value
$322,477
Previous $261,000
-0.0%
% of portfolio
0.08%
Previous 0.07%
Shares
6 transactions
Others Institutions Holding REGN
# of Institutions
1,466Shares Held
86.5MCall Options Held
2.38MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA9.05MShares$6.27 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.86 Billion0.2% of portfolio
-
State Street Corp Boston, MA4.69MShares$3.25 Billion0.09% of portfolio
-
Dodge & Cox San Francisco, CA4.55MShares$3.16 Billion1.47% of portfolio
-
Jpmorgan Chase & CO New York, NY4.07MShares$2.82 Billion0.15% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $74.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...